THE ANALYSIS STUDY OF VISUAL IMPAIRMENT AND BLINDNESS DUE TO MACULAR DISEASES: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/trc37476Keywords:
DME, AMD, blindness, macula, VEGF.Abstract
Background: DME and AMD are major causes of blindness, affecting the macula and central vision. AMD accounts for 8.7% of global blindness cases. Understanding AMD beyond the retina can provide insights into its pathophysiology, consequences, therapy, and clinical course. Anti-VEGF agents have shown promise in treating AMD, but a definitive treatment remains unidentified.
Methods: Following PRISMA 2020 guidelines, this systematic review concentrated on full-text English literature published between 2014 and 2024. Editorials and review articles that appeared in the same journal as the submission were not accepted without a DOI. A number of websites, including ScienceDirect, PubMed, and SagePub, were utilized to gather the literature.
Result: The study looked at more than 400 publications using reputable sources including Science Direct, SagePub, and PubMed. After it was decided that eight publications needed greater investigation, a more extensive review of the entire literature was carried out.
Conclusion: BCVA is crucial in the treatment of AMD and DME, with targeting VEGF being an effective approach. However, their effectiveness in other forms of AMD is less convincing. Chronic inflammation is a key factor in retinal diseases, including AMD. DME treatment requires a multidisciplinary approach, with anti-VEGF agents being the firstline treatment.
References
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3. PMID: 25104651.
Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol 2013;13:438-51.
Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-86.
Mandal A, Pal D, Agrahari V, Trinh HM, Joseph M, Mitra AK. Ocular delivery of proteins and peptides: challenges and novel formulation approaches. Adv Drug Deliv Rev 2018;126:67-95.
Agrawal S, Maity S, AlRaawi Z, Al-Ameer M, Kumar TKS. Targeting drugs against fibroblast growth factor(s)induced cell signaling. Curr Drug Targets 2021;22:214-40.
Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials. JAMA Ophthalmol 2018;136: 666-77.
Amini MA, Karbasi A, Vahabirad M, Khanaghaei M, Alizamir A. Mechanistic Insight into Age-Related Macular Degeneration (AMD): Anatomy, Epidemiology, Genetics, Pathogenesis, Prevention, Implications, and Treatment Strategies to Pace AMD Management. Chonnam Med J. 2023 Sep;59(3):143-159. doi:
4068/cmj.2023.59.3.143. Epub 2023 Sep 25. PMID: 37840684; PMCID: PMC10570864.
Yau JW, Rogers SL, Kawasaki R, et al.: Global prevalence and major risk factors of diabetic retinopathy . Diabetes Care. 2012, 35:556-64.
Bandello F, Battaglia Parodi M, Lanzetta P, Loewenstein A, Massin P, Menchini F, Veritti D: Diabetic macular edema. Dev Ophthalmol. 2010, 47:73-110. 10.1159/000320075
Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R: Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol Res. 2016, 103:149-57. 10.1016/j.phrs.2015.11.003
Miller K, Fortun JA: Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. Asia Pac J Ophthalmol (Phila).2018,7:28-35. 10.22608/APO.2017529
Fenwick EK, Xie J, Ratcliffe J, Pesudovs K, Finger RP, Wong TY, Lamoureux EL: The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci. 2012, 53:677-84. 10.1167/iovs.11-8992
Varma R, Bressler NM, Doan QV, et al.: Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014, 132:1334-40. 10.1001/jamaophthalmol.2014.2854
Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY: Treatment of diabetic macular edema. Curr Diab Rep. 2019, 19:68. 10.1007/s11892-019-1188-4
Khoramnia R, Nguyen QD, Kertes PJ, Sararols Ramsay L, Vujosevic S, Anderesi M, Igwe F, Eter N. Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema. Eye (Lond). 2024 Jan;38(1):54-60. doi: 10.1038/s41433-023-02637-2. Epub 2023 Jul 21. PMID: 37479803; PMCID: PMC10764750.
Vujosevic S, Alovisi C, Chakravarthy U. Epidemiology of geographic atrophy and its precursor features of intermediate age-related macular degeneration. Acta Ophthalmol. 2023 Dec;101(8):839-856. doi: 10.1111/aos.15767. PMID: 37933608.
Cheema AA, Cheema HR. Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies. Cureus. 2024 Jan 21;16(1):e52676. doi: 10.7759/cureus.52676. PMID: 38264181; PMCID: PMC10804209.
Cheng Z, Liu X. Comparing the efficacy of glucocorticoids and anti-VEGF in treating diabetic macular edema: systematic review and comprehensive analysis. Front Endocrinol (Lausanne). 2024 Mar 22;15:1342530. doi: 10.3389/fendo.2024.1342530. PMID: 38586457; PMCID: PMC10995385.
Salvetat ML, Pellegrini F, Spadea L, Salati C, Musa M, Gagliano C, Zeppieri M. The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When. J Clin Med. 2024 Feb 26;13(5):1327. doi: 10.3390/jcm13051327. PMID: 38592149; PMCID: PMC10932454.
Sepah YJ, Do DV, Mesquida M, Day BM, Blotner S, Afridi R, Halim MS, Hong K, Wakshull E, Fauser S, Stoilov I, Dong Nguyen Q; HARBOR; READ-3 Investigators. Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy. Eye (Lond). 2024 Jun;38(9):1755-1761. doi: 10.1038/s41433-024-03015-2. Epub 2024 Apr 15. PMID: 38622330; PMCID: PMC11156666.
Yao J, Lim J, Lim GYS, Ong JCL, Ke Y, Tan TF, Tan TE, Vujosevic S, Ting DSW. Novel artificial intelligence algorithms for diabetic retinopathy and diabetic macular edema. Eye Vis (Lond). 2024 Jun 17;11(1):23. doi: 10.1186/s40662-024-00389-y. PMID: 38880890; PMCID: PMC11181581.
Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet. 2014;15:151-71. doi: 10.1146/annurevgenom-090413-025610. Epub 2014 Apr 16. PMID: 24773320; PMCID: PMC4217162.
Grassmann F, Fleckenstein M, Chew EY, Strunz T, Schmitz-Valckenberg S, Göbel AP, Klein ML, Ratnapriya R, Swaroop A, Holz FG, Weber BH. Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration. PLoS One. 2015 May 11;10(5):e0126636. doi: 10.1371/journal.pone.0126636. PMID: 25962167; PMCID: PMC4427438.
Canfield AE, Hadfield KD, Rock CF, Wylie EC, Wilkinson FL. HtrA1: a novel regulator of physiological and pathological matrix mineralization? Biochem Soc Trans. 2007 Aug;35(Pt 4):669-71. doi: 10.1042/BST0350669. PMID: 17635117.
Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK; EVEREST II study group. Efficacy and Safety of Ranibizumab With or Without Verteporfin
Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2017 Nov 1;135(11):1206-1213. doi: 10.1001/jamaophthalmol.2017.4030. PMID: 28983556; PMCID: PMC5710379.
Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, Gomi F, Koh AH, Lee WK, Wong TY. Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. Ophthalmology. 2018 May;125(5):708-724. doi: 10.1016/j.ophtha.2017.11.019. Epub 2018 Jan 10. PMID: 29331556.
Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. 2016 May;73(9):1765-86. doi: 10.1007/s00018-016-2147-8. Epub 2016 Feb 6. PMID: 26852158; PMCID: PMC4819943.
Mesquida M, Drawnel F, Fauser S. The role of inflammation in diabetic eye disease. Semin Immunopathol. 2019 Jul;41(4):427-445. doi: 10.1007/s00281-019-00750-7. Epub 2019 Jun 7. PMID: 31175392.
Noma H, Yasuda K, Shimura M. Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema. Int J Mol Sci. 2021 Mar 26;22(7):3427. doi: 10.3390/ijms22073427. PMID: 33810434; PMCID: PMC8036935.
Kim JH, Jo E, Ryu S, Nam S, Song S, Han YS, et al. A deep learning ensem‐ ble method to visual acuity measurement using fundus images. NATO Adv Sci Inst Ser E Appl Sci. 2022;12:3190.
Paul W, Burlina P, Mocharla R, Joshi N, Li Z, Gu S, et al. Accuracy of artificial intelligence in estimating bestcorrected visual acuity from fundus photographs in eyes with diabetic macular edema. JAMA Ophthalmol. 2023;141(7):677–85.
Gurreri A, Pazzaglia A. Diabetic Macular Edema: State of Art and Intraocular Pharmacological Approaches. Adv Exp Med Biol. 2021;1307:375-389. doi: 10.1007/5584_2020_535. PMID: 32488606.
Tatsumi T. Current Treatments for Diabetic Macular Edema. Int J Mol Sci. 2023 May 31;24(11):9591. doi: 10.3390/ijms24119591. PMID: 37298544; PMCID: PMC10253534.
Namba R, Kaneko H, Suzumura A, Shimizu H, Kataoka K, Takayama K, Yamada K, Funahashi Y, Ito S, Nonobe N, Terasaki H. In Vitro Epiretinal Membrane Model and Antibody Permeability: Relationship With Anti-VEGF Resistance in Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2019 Jul 1;60(8):2942-2949. doi: 10.1167/iovs.19-26788. PMID: 31284311.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
